Q1 FY 2027 saw record revenue and profit growth, led by a 69% surge in CDMO and 10% rise in Affordable Medicines. Margins expanded, CapEx guidance was raised to meet robust demand, and the business remains diversified with strong outlook for CDMO and Bio segments.Based on Laurus Labs Ltd. [LAURUSLA…
Q1 FY27 saw 29% revenue growth and 126% net profit increase, driven by strong CDMO and Affordable Medicines performance. Gross and EBITDA margins expanded, with significant CAPEX and R&D investments supporting future growth.Original document: Laurus Labs Ltd. [LAURUSLABS] Slides Release — Jul. 24 2…
Revenue and net profit saw strong double-digit growth year-over-year and sequentially, with EPS more than doubling. Expansion activities included new investments and share allotments, while a major corporate restructuring awaits regulatory approval.Original document: Laurus Labs Ltd. [LAURUSLABS] I…
